TCGA-91-A4BC-01A-11R-A24H-07
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 59
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.500
- ALLOGRAFT_REJECTION+0.330
- INTERFERON_ALPHA_RESPONSE+0.330
- INTERFERON_GAMMA_RESPONSE+0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- IL6_JAK_STAT3_SIGNALING+0.280
- ANGIOGENESIS+0.240
- KRAS_SIGNALING_UP+0.170
- COAGULATION+0.160
- MYOGENESIS+0.160
Top 10 suppressed
- PROTEIN_SECRETION-0.590
- OXIDATIVE_PHOSPHORYLATION-0.570
- MYC_TARGETS_V1-0.560
- CHOLESTEROL_HOMEOSTASIS-0.510
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.470
- MTORC1_SIGNALING-0.460
- ANDROGEN_RESPONSE-0.450
- TGF_BETA_SIGNALING-0.440
- ADIPOGENESIS-0.430
- FATTY_ACID_METABOLISM-0.430
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934916 | — | — | 0.924 |
| 2 | SRR1473590 | GTEX | — | 0.909 |
| 3 | MNG1098 | — | — | 0.905 |
| 4 | SRR1338301 | GTEX | — | 0.903 |
| 5 | SRR1341057 | GTEX | — | 0.903 |
| 6 | SRR1322419 | GTEX | — | 0.901 |
| 7 | SRR1485167 | GTEX | — | 0.901 |
| 8 | SRR12202473 | — | — | 0.900 |
| 9 | SRR1358689 | GTEX | — | 0.900 |
| 10 | SRR1413454 | GTEX | — | 0.899 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.500 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.330 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.330 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| COAGULATION | 0.160 | Binimetinib | — uncovered |
| MYOGENESIS | 0.160 | Inavolisib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.140 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |